FDA approves oral dermatomyositis therapy - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

  • By

  • Kathryn Wighton

  • August 28, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of brepocitinib as the first oral treatment for dermatomyositis.

Approach:
  • Study Design: A phase 3 randomized, double-blind, multicenter, placebo-controlled study involving 241 adults with dermatomyositis.
  • Treatment Groups: Participants received either brepocitinib 30 mg, brepocitinib 15 mg, or placebo for 52 weeks.
  • Outcome Measures: Total Improvement Score at week 52, assessing muscle strength, physical function, skin disease activity, muscle enzymes, and overall health.
Key Findings:
  • Participants receiving brepocitinib 30 mg had a higher average Total Improvement Score compared to placebo.
  • Improvements in physical function and skin disease activity were observed in the 30 mg group.
  • 30 mg group participants were more likely to reduce corticosteroid use by week 48.
Interpretation:

Brepocitinib is the first FDA-approved oral therapy for dermatomyositis.

Limitations:
  • Adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea.
  • Treatment discontinuation due to adverse reactions occurred in 6% of the 30 mg group versus 11% in the placebo group.
Conclusion:

Brepocitinib is the first FDA-approved oral therapy for dermatomyositis, addressing a significant unmet need.

Sources:

Original Source(s)

FDA approves oral dermatomyositis therapy

  • by Kathryn Wighton

  • August 28, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Unexpected Diagnosis in Ring Finger Mass

Histopathology reveals digital actinomycosis in a young patient.

Vitiligo Gets Long-Missing Definitions for Severity and Relapse

A new international consensus framework standardizes how disease severity and relapse are defined, addressing inconsistencies that have complicated clinical trials and treatment decisions.